Company Overview and News

 
Singapore shares decline at Friday's open; STI down 0.55% to 3,052.84

18h businesstimes.com.sg
SINGAPORE stocks opened weaker on Friday, with the Straits Times Index declining 0.55 per cent or 16.83 points to 3,052.84 as at 9.03am after overnight declines in US markets.
SO7 UOVEF DBSDY BLVW AIQW U11 YSHLF D05 DBSDF UOVEY AMIW AMJW BS6

 
Singapore shares decline at Thursday's open; STI down 0.18% to 3,065.65

2018-10-18 businesstimes.com.sg
SINGAPORE stocks opened weaker on Thursday, with the Straits Times Index retreating 0.18 per cent or 5.45 points to 3,065.65 as at 9.02am after overnight declines in US markets.
5TY DBSDY D05 DBSDF

 
Singapore shares rise at Wednesday's open; STI up 1.61% to 3,083.05

2018-10-17 businesstimes.com.sg
SINGAPORE stocks opened higher on Wednesday, with the Straits Times Index gaining 1.61 per cent or 48.74 points to 3,083.05 as at 9.02am after US stocks rebounded overnight.
UOVEF DBSDY D05 DBSDF UOVEY 5WH U11

1
Bring on the pain: strategists say go defensive in Southeast Asian stocks

2018-10-16 bworldonline
SINGAPORE — With a little less than a quarter left of a year that’s already witnessed a trade war between the world’s two largest economies, higher oil prices and a still ongoing emerging-markets rout, what’s an investor in Southeast Asia to do?
NMR DBSDY PSKXF D05 8604 N33 DBSDF NRSCF PHSXY PSE MS

1
Bring on the Pain: Strategists Say Go Defensive in Asean Stocks

2018-10-16 theedgemarkets
(Oct 16): With a little less than a quarter left of a year that’s already witnessed a trade war between the world’s two largest economies, higher oil prices and a still ongoing emerging-markets rout, what’s an investor in Southeast Asia to do?
NMR DBSDY PSKXF D05 8604 N33 DBSDF NRSCF PHSXY PSE MS

 
Singapore shares rise at Tuesday's open; STI up 0.38% to 3,057.60

2018-10-16 businesstimes.com.sg
SINGAPORE stocks opened stronger on Tuesday, with the Straits Times Index increasing 0.38 per cent or 11.63 points to 3,057.60 as at 9.02am.
DBSDY G13 D05 DBSDF GIGNF GIGNY

 
The problem with DFIs in Malaysia

2018-10-15 theedgemarkets
LAST week, Bank Pembangunan Malaysia Bhd (BPMB) appointed Afidah Mohd Ghazali as its chief financial officer, acting president and CEO. If she makes it past the “acting” stage, she will be the bank’s third CEO in a span of three years, and all eyes will be on her to see how long she lasts.
DBSDY D05 DBSDF

 
Buybacks rise and SLA plc adds to its AEM stake

2018-10-14 businesstimes.com.sg
FOR the 2018 year through to Oct 11, the Straits Times Index (STI) has generated a 7.4 per cent decline in total return, which is perched in the middle of regional moves that have ranged from a 4.2 per cent total return for the Nikkei 225 Index to a 22.8 per cent decline for China's CSI 300 Index.
5UX DBSDY SLVFF BLH SQG FIN SPKMF HAWPY D05 DBSDF N2IU 5CP AWX A13 HAWPF

 
Singapore stocks: STI resumes Friday afternoon at 3,058.65, up 0.37% on day

2018-10-12 businesstimes.com.sg
SINGAPORE stocks rose on Friday afternoon's trading resumption, with the Straits Times Index climbing 11.26 points or 0.37 per cent on the day to 3,058.65 as at 1.03pm.
DBSDY G13 D05 DBSDF GIGNF GIGNY

 
Singapore stocks: STI resumes Thursday afternoon at 3,045.92, down 2.7% on day

2018-10-11 businesstimes.com.sg
SINGAPORE stocks fell on Thursday afternoon's trading resumption, with the Straits Times Index declining 85.56 points or 2.7 per cent on the day to 3,045.92 as at 1.03pm.
DBSDY G13 D05 DBSDF GIGNF GIGNY

 
Singapore stocks: STI resumes Wednesday afternoon at 3,145.21, down 0.68% on day

2018-10-10 businesstimes.com.sg
SINGAPORE stocks fell on Wednesday afternoon's trading resumption, with the Straits Times Index declining 21.39 points or 0.68 per cent on the day to 3,145.21 as at 1.01pm.
NCMHF DBSDY D05 N4E A31 DBSDF

 
Singapore stocks: STI resumes Tuesday afternoon at 3,171.39, down 0.32% on day

2018-10-09 businesstimes.com.sg
SINGAPORE stocks fell on Tuesday afternoon's trading resumption, with the Straits Times Index declining 10.06 points or 0.32 per cent on the day to 3,171.39 as at 1.01pm.
NCMHF DBSDY D05 N4E DBSDF 545

 
Singapore stocks: STI resumes Monday afternoon at 3,194.38, down 0.48% on day

2018-10-08 businesstimes.com.sg
SINGAPORE stocks fell on Monday afternoon's trading resumption, with the Straits Times Index declining 15.41 points or 0.48 per cent on the day to 3,194.38 as at 1.01pm.
5TY NCMHF UOVEF DBSDY D05 N4E DBSDF UOVEY U11

 
Singapore shares decline at Friday's open; STI down 0.18% to 3,225.85

2018-10-05 businesstimes.com.sg
SINGAPORE stocks opened lower on Friday, with the Straits Times Index falling 0.18 per cent or 5.74 points to 3,225.85 as at 9.01am after overnight declines in US markets.
UOVEF DBSDY D05 DBSDF UOVEY 5WH U11

 
Singapore shares close down by 1.1% on Thursday; STI ends at 3,231.59

2018-10-04 businesstimes.com.sg
SINGAPORE stocks tracked a regional decline on Thursday, with the Straits Times Index falling by 35.81 points, or 1.1 per cent, to 3,231.59.
DBSDY D05 DBSDF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...